Author Affiliations: Department of Ophthalmology and the Francis I. Proctor Foundation, University of California, San Francisco, and Department of Ophthalmology, San Francisco General Hospital.
The use of autologous serum for treating ocular surface disorder has a long history that dates back at least to the 1970s when autologous serum was used via a mobile ocular perfusion pump to treat ocular alkali burns.1 Subsequently, a report2 in the rheumatologic literature appeared in 1984 discussing the use of autologous serum as a tear substitute. Although probably used more often than it was publicized to be, the use of autologous serum for the treatment of ocular surface disorder did not appear to garner widespread interest until the late 1990s (Figure). Since that time, this treatment modality has become increasingly popular, and the indications for its use have expanded rapidly. However, despite the reported successes of the use of this product, there are clinical and nonclinical concerns about this therapy that must also be addressed.
Jeng BH. Use of Autologous Serum in the Treatment of Ocular Surface Disorders. Arch Ophthalmol. 2011;129(12):1610–1612. doi:10.1001/archophthalmol.2011.336
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: